Background: It is likely that improved treatment of diabetes during the last decades has led to a declining prevalence of retinopathy. We have assessed whether this is the case for patients with type I diabetes.
Material And Methods: Medical records were retrospectively reviewed for all patients who were diagnosed with type 1 diabetes in the periods 1960-1975 (early group) and 1985-1990 (late group) at the diabetes clinic in St. Olavs Hospital (Trondheim). Information on the prevalence of retinopathy ten and 15 years after diabetes onset was obtained from hospital records and private ophthalmologists in Trondheim.
Results: 125 patients were identified in the early group and 147 patients in the late group. The prevalence of proliferative retinopathy was higher in the early group than in the late group, both after ten years (4% vs. 0%, p = 0.04) and 15 years (13% vs. 5%, p = 0.04) of diabetes. The prevalence of background retinopathy was not significantly different between the two groups after ten (12% vs. 14%, p = 0.70) or 15 years (29% vs. 24%, p = 0.36) of diabetes.
Interpretation: Our results indicate that the prevalence of proliferative retinopathy is decreasing in patients with type 1 diabetes in Norway. Explanations may be improved follow-up and treatment of diabetes and diabetic retinopathy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4045/tidsskr.09.0490 | DOI Listing |
Clin Ophthalmol
December 2024
Department of Ophthalmology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Purpose: To evaluate the anatomical and visual outcomes of patients with rhegmatogenous retinal detachment (RRD) who received primary repair by combined pars plana vitrectomy with scleral buckling (PPV/SB) or pars plana vitrectomy (PPV) alone by using a propensity analysis.
Patients And Methods: This study was a single center retrospective observational study. Medical records of patients who underwent surgical interventions between January 2013 and December 2019 were retrospectively reviewed.
Probl Radiac Med Radiobiol
December 2024
State Institution «National Research Center of Radiation Medicine, Hematology and Oncology of the National Academy of Medical Sciences of Ukraine», 53 Yuriia Illienka Str., Kyiv, 04050, Ukraine.
Objective: analysis of molecular genetic phenotypes, their proliferative activity, degree of spread and differentiation of tumors in breast cancer patients affected by the accident at the Chornobyl Nuclear Power Plant.
Materials And Methods: 96 breast cancer patients who were exposed to ionizing radiation as a result of the accident at the Chornobyl Nuclear Power Plant were examined. Clinical, radiological, instrumental, morphological,immunohistochemical research methods were used.
J Transl Med
December 2024
Department of Ophthalmology, Zhujiang Hospital, Southern Medical University, 253 Industrial Avenue, Guangzhou, 510282, China.
Background: Diabetic retinopathy (DR) is the most important complication of Type 2 Diabetes (T2D) in eyes. Despite its prevalence, the early detection and management of DR continue to pose considerable challenges. Our research aims to elucidate potent drug targets that could facilitate the identification of DR and propel advancements in its therapeutic strategies.
View Article and Find Full Text PDFEur J Haematol
December 2024
Department of Ophthalmology and Visual Sciences, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, USA.
Background/aim: A few shave identified systemic and hematologic risk factors for Proliferative Sickle Cell Retinopathy (PSR) development. The relevance of healthcare utilization as a risk factor for PSR has not been defined. This study evaluates patterns of healthcare utilization among patients with sickle cell disease (SCD) and retinopathy.
View Article and Find Full Text PDFBiochem Pharmacol
December 2024
Department of Human Anatomy and Cell Science, Winnipeg, MB, Canada; Department of Pathology, University of Manitoba, Rady Faculty of Health Sciences, Max Rady College of Medicine, Winnipeg, MB, Canada; CancerCare Manitoba, Winnipeg, MB, Canada; Children's Hospital Research Institute of Manitoba (CHRIM), Winnipeg, MB, Canada. Electronic address:
Glioblastoma (GB) is the most prevalent and aggressive primary brain tumor with fatal outcome due to a lack of effective treatments. We previously identified C1q-tumor necrosis factor-related protein 8 (CTRP8), a new member of the adiponectin family, as a novel agonist of the relaxin family peptide receptor 1 (RXFP1) and showed that the CTRP8-RXFP1 ligand-receptor system facilitates increased invasiveness and chemoresistance in GB cells. In the present study, we have investigated the role of the CTRP8-RXFP1 signaling axis in glioma progression using an orthotopic mouse model xenografted with human U251 glioma cells stably expressing CTRP8 and RXFP1.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!